Analysts Offer Predictions for CG Oncology FY2029 Earnings

CG Oncology, Inc. (NASDAQ:CGON) – Analysts at HC Wainwright boosted their FY2029 earnings per share (EPS) estimates for CG Oncology in a research note issued on Tuesday, April 7th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of $3.12 per share for the year, up from their prior forecast of $2.79. HC Wainwright currently has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for CG Oncology’s FY2030 earnings at $6.06 EPS.

A number of other equities research analysts have also recently commented on CGON. Royal Bank Of Canada lifted their price objective on CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Wall Street Zen cut CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Truist Financial boosted their target price on CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. The Goldman Sachs Group reissued a “buy” rating and issued a $82.00 target price on shares of CG Oncology in a research note on Monday, January 12th. Finally, Piper Sandler boosted their target price on CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $70.67.

CG Oncology Stock Down 1.3%

Shares of CG Oncology stock opened at $68.87 on Wednesday. CG Oncology has a 12 month low of $14.80 and a 12 month high of $71.90. The business has a fifty day simple moving average of $60.03 and a 200 day simple moving average of $49.02. The stock has a market cap of $5.81 billion, a PE ratio of -33.27 and a beta of 0.70.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.10. The company had revenue of $2.32 million for the quarter.

Insider Transactions at CG Oncology

In other CG Oncology news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $52.47, for a total value of $584,778.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Whittier Trust Co. of Nevada Inc. acquired a new position in CG Oncology in the fourth quarter valued at about $27,000. Strengthening Families & Communities LLC bought a new stake in shares of CG Oncology in the third quarter valued at about $40,000. Comerica Bank lifted its holdings in shares of CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares in the last quarter. Picton Mahoney Asset Management bought a new stake in shares of CG Oncology in the fourth quarter valued at about $118,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of CG Oncology by 33.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after purchasing an additional 972 shares in the last quarter. 26.56% of the stock is owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.